KEGG   DRUG: LampalizumabHelp
Entry
D10440                      Drug                                   

Name
Lampalizumab (USAN/INN)
Formula
C2068H3214N546O676S13
Exact mass
46929.0273
Mol weight
46957.7444
Sequence
(Heavy chain)
EVQLVQSGPE LKKPGASVKV SCKASGYTFT NYGMNWVRQA PGQGLEWMGW INTYTGETTY
ADDFKGRFVF SLDTSVSTAY LQISSLKAED TAVYYCEREG GVNNWGQGTL VTVSSASTKG
PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL
SSVVTVPSSS LGTQTYICNV NHKPSNTKVD KKVEPKSCDK THT
(Light chain)
DIQVTQSPSS LSASVGDRVT ITCITSTDID DDMNWYQQKP GKVPKLLISG GNTLRPGVPS
RFSGSGSGTD FTLTISSLQP EDVATYYCLQ SDSLPYTFGQ GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(disulfide bridges: H22-H96, H142-H198, H218-L214, L23-L88, L134-L194)
  Type
Peptide
Efficacy
Aging-related macular degeneration therapeutic agent
Comment
Monoclonal antibody
Treatment of geographic atrophy secondary to age-related macular degeneration
Target
CFD [HSA:1675] [KO:K01334]
Brite
Target-based classification of drugs [BR:br08310]
 Enzymes
  Hydrolases (EC3)
   Serine peptidases
    CFD
     D10440  Lampalizumab (USAN/INN)
BRITE hierarchy
Other DBs
CAS: 1278466-20-8
PubChem: 172232533
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system